POHMS wants to thank our corporate sponsors. With your support we are able to fulfill the mission of this organization which is to improve the business conditions of the hematology oncology practice.
Please see information below for 2021 Corporate Sponsorship:
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease.
At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.
CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices. CHOC's current preferred vendor is McKesson Specialty Health.
CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.
CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for almost 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 40 projects in the pipeline. The company is the leading provider of anti-tumor therapeutics in theUnited States. With its strength in all areas of the drug development process — from research and development to manufacturing and commercialization — Genentech continues to transform innovative science into breakthrough therapies for patients. For more general information about the company, visit our corporate overview section.
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in the U.S., Europe and Japan.
McKesson empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our community oncology practice customers and help them provide quality care for patients.
TAKEDA ONCOLOGY (formerly known as MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY) endeavors to deliver novel medicines to cancer patients worldwide through our science, innovation and passion for improving patients’ lives. We know this mission is not an easy one but we are up to the task: we aspire to cure cancer.
About AbbVie in Oncology
Astellas Pharma US INC
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease.
Built upon a rich legacy of innovative "firsts" Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology and nephrology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.
Rooted in rich scientific collaborations and community-based relationships, we have access to some of the top minds in science today, allowing us to advance the treatment of patients through our innovative medicines. Our discoveries lead us not only to new treatments, but also to new ways to empower patients and expand their access to quality care – because we believe that changing lives for the better takes more than medicine.
Lilly is a pioneer in chemotherapy drugs, having introduced vincristine and vinblastine in the 1960s. These anticancer drugs, known as vinca alkaloids, were derived from the rosy periwinkle plant. In 1996, Lilly leveraged this expertise with the introduction of GEMZAR® (gemcitabine HCl for injection) for the treatment of non-small cell lung cancer, pancreatic cancer, and metastatic breast cancer.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.
Oncology Supply is the nation’s largest distributor of Chemotherapy drugs & Supplies, earning a respected name in the wholesale specialty arena with more than 30 years of experience. For the community-based oncology practice, Oncology Supply has become the first choice for reliability, stability, integrity and honesty. Bringing technology to the forefront, Oncology Supply’s Nucleus® cabinet offers support and solutions for your practice’s inventory management needs. Our goal is to deliver responsive and innovative solutions to help our business partners positively impact cancer patients’ lives. For more information, visit www.oncologysupply.com.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. In 2000, the Company was formed by some of Sweden’s most leading scientists with ties preeminent oncology research institutions. Oncopeptides’ headquarters is in Stockholm, Sweden with a U.S. headquarters in Boston, Massachusetts. In addition to Boston, Oncopeptides has a footprint in Los Altos, California, another U.S. biotech
Sanofi's focus on patients has driven our historical and ongoing strategy to create long-term value by researching and delivering the best treatments. Sanofi’s oncology heritage has given us an extensive knowledge base that enriches our current research expertise. This experience encompasses a wide variety of cancer types, disease stages, patient populations, and patient needs. As a global healthcare company focused on patient needs, we are committed to attacking cancer on all fronts.
Taiho Oncology Inc
Sponsors & Exhibitors
BriovaRx is a leading specialty pharmacy services company dedicated to helping administer and deliver high-quality, cost-effective specialty pharmacy care. BriovaRx combines technology, data and expertise to provide educational resources, 24/7 pharmacy support and trusted advice to the individuals, caregivers and care teams we serve. Our pharmacy, clinical and business experts work closely to ensure that every patient gets the personalized support they need to manage their complex conditions and medical therapies.
Bayer HealthCare Pharmaceuticals, Inc.
At Bayer our mission is Science For A Better Life. Bayer HealthCare discovers and manufactures innovative products that will improve human health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease.
Boehringer Ingelheim Oncology
Caris Life Sciences
In the first quarter of 2008, Eisai, Inc. purchased MGI Pharma. Eisai Inc. (pronounced â-zî) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ending March 31, 2007).
Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd.., which has a strong and lasting commitment to the U.S. market.
Genoptix Medical Laboratory
Onco 360, Oncology Pharmacy
Pfizer Oncology Patient Assistance